Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambisome timing in febrile neutropenia
NCT00003938Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 1999
- Primary completion
- May 2003
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of amphotericin b in febrile neutropenia (FN) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Efficacy of amphotericin B-liposomal formulation and Side effects of amphotericin B-liposomal formulation. Started Jun 1999; status: completed.
02
Drugs
amphotericin b
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT00003938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003938.